Safety and clinical outcomes in endovascular treatment for symptomatic cerebral venous thrombosis: a single-center experience with meta-analysis

Tang, Si Zhao; Jing, Mingxue; Yang, Chao; Yeo, Leonard Ll; Tan, Benjamin Yong‐Qiang; Chan, Bernard P.L.; Vijay, Kumar Sharma; Teoh, Hock-Luen; Gopinathan, Anil

doi:10.1007/s10143-023-02012-5

Cited by 7 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 Endovascular treatment (EVT) should be considered for patients with neurological deterioration despite anticoagulation or sever venous stroke, presenting with worsening neurological symptoms, cortical venous outflow stasis, intracerebral hemorrhage, deep venous thrombosis, worsening seizures and coma. 32 , 33 Although the TO‐ACT trial did not demonstrate a significant improvement in functional outcome for patients with venous stroke who underwent EVT with standard medical care, some studies suggest that patients with severe venous stroke may benefit from EVT. 34 , 35 The VENOST study demonstrated that the functional outcome of venous stroke in patients with BD was positive; only 12% of patients who presented with altered consciousness and cranial nerve involvement had poor outcomes (mRS ≥ 2).…”

Section: Venous Stroke In Patients With Autoimmune Diseasesmentioning

confidence: 99%

Cerebral venous thrombosis in patients with autoimmune disease, hematonosis or coronavirus disease 2019: Many familiar faces and some strangers

et al. 2023

View full text Add to dashboard Cite

BackgroundCerebral venous thrombosis, a rare stroke, is characterized by neurological dysfunction caused by bleeding and/or infarction resulting from venous sinus thrombosis, the so‐called venous stroke. Current guidelines recommend anticoagulants as first‐line therapy in the treatment of venous stroke. With complicated causes of cerebral venous thrombosis, treatment is difficult, especially when combined with autoimmune diseases, blood diseases, and even COVID‐19.AimsThis review summarizes the pathophysiological mechanisms, epidemiology, diagnosis, treatment, and clinical prognosis of cerebral venous thrombosis combined with autoimmune diseases, blood diseases, or infectious diseases such as COVID‐19.ConclusionA systematic understanding of particular risk factors that should not be neglected when unconventional cerebral venous thrombosis occurs and for a scientific understanding of pathophysiological mechanisms, clinical diagnosis, and treatment, thus contributing to knowledge on special types of venous stroke.

show abstract